Cargando…

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study

BACKGROUND: Some prospective studies have shown that second‐generation tyrosine kinase inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations. However, studies comparing second‐line chemotherapy eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chien‐Yu, Hu, Chia‐Hao, Hsu, Chia‐Fu, Tsai, Jeng‐Shiuan, Chen, Chian‐Wei, Lin, Chia‐Yin, Chang, Chao‐Chun, Yen, Yi‐Ting, Tseng, Yau‐Lin, Su, Po‐Lan, Lin, Chien‐Chung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317592/ https://www.ncbi.nlm.nih.gov/pubmed/37183851 http://dx.doi.org/10.1111/1759-7714.14930

Ejemplares similares

Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Chu, Chang-Yao, et al.
Publicado: (2023)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023)

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2021)

Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
por: Lin, Chia-Ying, et al.
Publicado: (2019)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
por: Tsai, Jeng-Shiuan, et al.
Publicado: (2022)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wu, Qiang, et al.
Publicado: (2021)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody
por: Lin, Yu-Wei, et al.
Publicado: (2022)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment
por: Hung, Hsiu-Ying, et al.
Publicado: (2016)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

S100A9(+) MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
por: Feng, Po-Hao, et al.
Publicado: (2018)

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC
por: Cheng, Fang-Ju, et al.
Publicado: (2020)

Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
por: Feng, Po-Hao, et al.
Publicado: (2018)

Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study
por: Hata, Tae, et al.
Publicado: (2023)

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2021)

Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study
por: He, Zhi-Yong, et al.
Publicado: (2019)

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
por: Su, Po-Lan, et al.
Publicado: (2022)

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
por: Su, Po-Lan, et al.
Publicado: (2018)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
por: Li, Kaidi, et al.
Publicado: (2017)

The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
por: Chen, Ying-Yuan, et al.
Publicado: (2022)

Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
por: Ling, Yun, et al.
Publicado: (2016)

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
por: Su, Po‐Lan, et al.
Publicado: (2020)

Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses
por: Su, Sheng-Fang, et al.
Publicado: (2021)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
por: Wang, Hongbiao, et al.
Publicado: (2022)

Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR‑TKI resistance in EGFR mutant non-small cell lung cancer
por: Chen, Junjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_enbc115apvkgaub0osdsa2bsh2